Introducing Melanoma Institute Australia's Conjoint Medical Directors
14 March 2017
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Professor Long is a world-renowned clinical medical oncologist and melanoma researcher who is also President Elect for the prestigious international Society for Melanoma Research. She leads an extensive clinical trials team and research laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma.
Professor Scolyer is a world- leading surgical pathologist and melanoma researcher who has authored more than 450 seminal publications on this disease. Professor Scolyer’s expertise has already delivered exponential improvements in diagnosis and the staging of melanoma which determines a patient’s treatment pathway.
Together with their colleagues at MIA, they are changing the face of melanoma diagnosis and treatment in Australia and around the world.
‘Quite simply, I want to make a difference,” Professor Long said. ‘’I’d love to eradicate melanoma and put ourselves out of a job. That is the ultimate goal.”
‘Even if we haven’t eradicated melanoma in the next five years, I’d like to think we can control it long term so people don’t die of this disease,” Professor Scolyer added.
Sharing the Medical Director role means double the expertise and double the perspective on challenges. Both Professors believe their partnership will be crucial to leading Melanoma Institute Australia towards breaking new ground in melanoma diagnosis and treatment.
‘We know that ultimately prevention is better than cure, so we have to attack the disease at different levels from education, prevention, screening, early diagnosis, and by providing the best early treatment for the best outcomes,’ Professor Scolyer said.
‘The key to tackling melanoma is definitely collaboration, communication and sharing knowledge,” Professor Long added.
Melanoma Institute Australia is the leading centre in the world with a single focus on melanoma care, research and education.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.